Live Quote · NASDAQKRTXHealthcare· Biotechnology

Karuna Therapeutics, Inc.

$329.83 0.03%(+$0.09)
TickerSpark Score
56/100
Mixed
50
Valuation
35
Profitability
10
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRTX research report →

52-Week Range100% of range
Low
$158.38
Current
$329.83
High
$329.99
Company Overviewwww.karunatx.com

About the company

Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors.

CEO
William Meury
IPO
2019
Employees
339
HQ
Boston, MA, US

Price Chart

+72.12% · this period
$329.83$245.42$161.01Mar 17Sep 18Mar 18
Valuation
Market Cap
$12.60B
P/E
-28.12
P/S
19264.95
P/B
9.72
EV/EBITDA
-25.21
Div Yield
0.00%
Profitability
Gross Margin
-160.09%
Op Margin
-75653.98%
Net Margin
-66311.93%
ROE
-36.44%
ROIC
-38.93%
Growth & Income
Revenue
$654.00K · -93.85%
Net Income
$-433,680,000 · -56.94%
EPS
$-11.73 · -34.21%
Op Income
$-494,777,000
FCF YoY
-69.81%
Performance & Tape
52W High
$329.99
52W Low
$158.38
50D MA
$317.38
200D MA
$228.31
Beta
1.15
Avg Volume
971.83K

Get TickerSpark's AI analysis on KRTX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 18, 24Wheadon David E.sell25,000
Mar 18, 24Wheadon David E.sell8,500
Mar 18, 24Wheadon David E.sell990
Mar 18, 24Wheadon David E.sell5,000
Mar 18, 24Wheadon David E.sell1,904
Mar 18, 24Torres Denicesell990
Mar 18, 24Torres Denicesell5,000
Mar 18, 24Torres Denicesell1,904
Mar 18, 24Torres Denicesell8,500
Mar 18, 24Torres Denicesell25,000
Coverage · KRTX

Our KRTX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on KRTX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate KRTX report →
Internal Compare

Similar companies

Peers in the same neighborhood.